GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma

GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma

Show other versions (1)

Epidermal Growth Factor Receptor (EGFR) is amplified in over 50% of glioblastomas and promotes tumor formation and progression. However, attempts to treat glioblastoma with EGFR tyrosine kinase inhibitors have been unsuccessful thus far. The current standard of care is especially poor in patients wi...

Full description

Bibliographic Details
Main Authors: Alphonse, M.P (Author), Bordeaux, Z.A (Author), Braun, G. (Author), Choi, J. (Author), Davis, C. (Author), Kwatra, M.M (Author), Kwatra, S.G (Author), McKeel, J. (Author), Miller, M.N (Author), Nanni, C. (Author), Sutaria, N. (Author), West, C.E (Author)
Format: Article
Language:English
Published: MDPI 2022
Subjects:
EGFR
EGFRvIII
glioblastoma
glioblastoma stem cells
super-enhancer
Online Access:View Fulltext in Publisher

Similar Items

Similar Items